- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.